$AMRI (Albany Molecular Research Inc.)

$AMRI {{ '2015-12-10T14:16:32+0000' | timeago}} • Announcement

Contract research and manufacturing company $AMRI said it entered into a three-year agreement with Multispan, a biotechnology company, to co-market their G protein-coupled receptor (GPCR) drug discovery services to global pharmaceutical and biotechnology clients.

$MDT {{ '2018-01-16T17:16:57+0000' | timeago}} • Announcement

$MDT received FDA clearance of the Riptide Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio. This is designed to retrieve thrombus (or blood clot) through the Arc Catheter and restore blood flow in patients experiencing blockage of an artery in the brain, known as an ischemic stroke.

$CRL {{ '2018-01-16T14:14:39+0000' | timeago}} • Announcement

$CRL appointed Jean-Paul Mangeolle, former President of AB SCIEX, to its BoD. As a member of the Board, he will serve on the Audit and Compensation Committees.

$CRL {{ '2018-01-11T13:12:01+0000' | timeago}} • Announcement

Drug research solutions provider $CRL has acquired KWS BioTest, a contract research organization, for about $20MM. The deal also includes a potential additional payment of up to $4MM based on future performance. The acquisition is not expected to be material to Charles River’s GAAP or non-GAAP results from operations this year.

$DEPO {{ '2018-01-10T17:44:57+0000' | timeago}} • Announcement

$DEPO announced the closing of its Commercialization Agreement for the US rights to commercialize both NUCYNTA Extended Release and NUCYNTA Immediate Release with Collegium Pharmaceutical Inc. In connection with the closing, $DEPO received an upfront $10MM cash payment from Collegium.

$MDT {{ '2018-01-10T14:44:35+0000' | timeago}} • Announcement

The FDA has approved an innovative clinician programmer for the SynchroMed-II Intrathecal Drug Delivery system developed by medical technology company $MDT, for chronic pain and spasticity. SynchroMed-II, an implantable pump, delivers medication directly to the fluid around the spinal cord. It is an app that facilitates simple, guided workflows.

$MLNT {{ '2018-01-08T17:08:01+0000' | timeago}} • Announcement

$MLNT completed the acquisition of $MDCO’s infectious disease business. $MLNT also announced that $MDCO’s Mike McGuire has joined the new organization as SVP, Commercial, replacing Chief Commercial Officer, John Temperato, who left $MLNT to pursue other opportunities.

$MDCO {{ '2018-01-08T13:17:52+0000' | timeago}} • Announcement

Pharma firm $MDCO closed the sale of its infectious disease business to $MLNT for $215MM of guaranteed cash and 3.3 MM common shares of Melinta. The sale consideration also includes royalty payments of 5-25% on certain drug sales and the assumption by Melinta of all royalty, milestone and other payment obligations relating to those products.

$OSUR {{ '2018-01-04T13:33:43+0000' | timeago}} • Announcement

Diagnostic devices maker $OSUR has named Stephen Tang President and CEO, effective April 1, 2018, to succeed Douglas Michels who will be retiring in March. Tang will step down as Chairman, but continue as a Director. Meanwhile, Ronald Spair will retire as CFO and COO later this year. Further, OraSure revised up its 4Q17 revenue guidance to $50MM.

$MYGN {{ '2018-01-03T13:32:07+0000' | timeago}} • Announcement

$MYGN said $AZN will use its myChoice HRD Plus test in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza & Avastin. Under the agreement, $MYGN will use its myChoice Plus test to evaluate patients enrolled in an ongoing Phase III trial. Financial terms were not disclosed.

$ACET {{ '2018-01-02T20:11:33+0000' | timeago}} • Announcement

$ACET's finished dosage form generics subsidiary Rising Pharmaceuticals launched the first generic for Efavirenz Capsules. This is an FDA-approved generic version of the reference listed drug, Sustiva from $BMY, which in combination with other drugs is indicated for the treatment of HIV-1 infection in adults and pediatric patients.

$ZBH {{ '2017-12-19T14:31:26+0000' | timeago}} • Announcement

$ZBH appointed Bryan Hanson as President and CEO and a member of the BoD, effective Dec. 19, 2017. Daniel Florin, who has served as Interim CEO since July 11, 2017, will continue in his role as SVP and CFO. Most recently, Hanson served as a $MDT's Executive Committee member and as EVP and President of Medtronic's Minimally Invasive Therapies Group.

$MDT {{ '2017-12-19T14:11:39+0000' | timeago}} • Announcement

$MDT has named Bob White, previously SVP and President of APAC Region, as EVP and President of Minimally Invasive Therapies Group. The company also announced Chris Lee, SVP and President of Greater China Region, will assume the position of APAC Region President. These leadership changes are effective immediately.

$MDT {{ '2017-12-08T21:21:14+0000' | timeago}} • Announcement

$MDT BoD approved 3Q18 cash dividend of $0.46 per ordinary share, representing a 7% increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in June 2017.

$ACET {{ '2017-12-07T22:37:45+0000' | timeago}} • Announcement

$ACET has declared a regular quarterly dividend of $0.065 per common share, payable on December 28, 2017 to shareholders of record as of December 18, 2017.

$DEPO {{ '2017-12-04T22:44:23+0000' | timeago}} • Announcement

$DEPO signed a commercialization agreement with Collegium Pharmaceutical, Inc. For the first four years, $DEPO will receive a minimum royalty of $135MM per year. After year four, the royalty mechanism remains the same but without a minimum. The royalty rate will be adjusted post patent expiry, which is not expected until late 2025.

$DEPO {{ '2017-12-04T22:44:05+0000' | timeago}} • Announcement

$DEPO signed a commercialization agreement with Collegium Pharmaceutical, Inc., under which Collegium will commercialize NUCYNTA Extended Release and NUCYNTA Immediate Release. For this, $DEPO will receive a royalty rate on all NUCYNTA revenues based on certain net sales thresholds. The deal is expected to close in early Jan. 2018.

$MLNT {{ '2017-11-29T12:50:38+0000' | timeago}} • Announcement

Novel antibiotics developer $MLNT to acquire the infectious disease business of $MDCO. The purchase price also includes a payment by $MLNT to $MDCO of $25MM following each of the 12 and 18 month anniversaries of the closing date and payment to $MDCO of some royalty payments, based on tiered net sales of the acquired products in some jurisdictions.

$MLNT {{ '2017-11-29T12:49:30+0000' | timeago}} • Announcement

Novel antibiotics developer $MLNT to acquire the infectious disease business of $MDCO. The purchase price consists of a payment by $MLNT to $MDCO of $165MM in cash and issuance of shares equal to $50MM of Melinta stock, divided by 90% of volume weighted avg. price for the trailing 10 trading day period ending 3 trading days prior to closing.

$MLNT {{ '2017-11-29T12:47:52+0000' | timeago}} • Announcement

Novel antibiotics developer $MLNT to acquire the infectious disease business of $MDCO, which includes three marketed products: recently approved and launched Vabomere (vaborbactam/meropenem), and established commercial products Orbactiv (oritavancin) and Minocin IV (minocycline). The acquisition is expected to close in 1Q18.

$MDT {{ '2017-11-22T20:29:59+0000' | timeago}} • Webcast

In Oct., Animas announced to cease the manufacture and sale of its insulin pumps and partnered with $MDT to offer its customers the opportunity to transfer to a new device.With $JNJ exiting the insulin pump market in the US and Canada, $MDT now has access to the 90,000 patients who use Animas insulin pumps.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
XON (Intrexon Corporation)
Thursday, November 9 2017 - 10:30pm
ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
CRL (Charles River Laboratories International, Inc.)
Thursday, November 9 2017 - 1:30pm
DEPO (DepoMed Inc.)
Tuesday, November 7 2017 - 9:30pm
CBM (Cambrex Corporation.)
Tuesday, November 7 2017 - 1:30pm
CAH (Cardinal Health, Inc.)
Monday, November 6 2017 - 1:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
ACET (Aceto Corp.)
Friday, November 3 2017 - 1:00pm
SNMX (Senomyx Inc.)
Thursday, November 2 2017 - 9:00pm
OSUR (OraSure Technologies, Inc.)
Wednesday, November 1 2017 - 9:00pm
EXEL (Exelixis, Inc.)
Wednesday, November 1 2017 - 9:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
INCY (Incyte Corporation)
Tuesday, October 31 2017 - 2:00pm
EXAS (Exact Sciences Corporation)
Monday, October 30 2017 - 9:00pm
ICLR (ICON Public Limited Company)
Thursday, October 26 2017 - 2:00pm
Q (Quintiles Transnational Holdings Inc.)
Thursday, October 26 2017 - 1:00pm
MDCO (The Medicines Company)
Wednesday, October 25 2017 - 12:30pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm

AlphaGraphics you may like